Innate Pharma (IPHA) Net Cash Flow (2019 - 2024)

Innate Pharma (IPHA) has reported Net Cash Flow for 6 consecutive years, with -$6.8 million the latest figure, recorded in Q4 2024.

• Quarterly Net Cash Flow fell 205.6% year-over-year to -$6.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$11.8 million (up 23.71% YoY) and the FY2025 annual result came in at -$44.8 million, down 963.61% from the prior year.
• Net Cash Flow fell to -$6.8 million in Q4 2024 per IPHA's latest filing, from -$4.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for IPHA reached as high as -$1.1 million in Q2 2022 and fell as low as -$6.8 million in Q4 2024.
• A 5-year average of -$2.5 million and a median of -$1.4 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow advanced 21.7% — and 2024, when it slumped 247.27%.
• Year by year, Net Cash Flow stood at -$1.3 million in 2020, then decreased by 4.16% to -$1.4 million in 2021, then slumped by 49.1% to -$2.1 million in 2022, then declined by 7.55% to -$2.2 million in 2023, then sank by 205.6% to -$6.8 million in 2024.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$6.8 million, -$4.9 million, and -$2.2 million for Q4 2024, Q2 2024, and Q4 2023 respectively.